Melanoma
Conditions
Keywords
Locally Advanced or Metastatic Melanoma
Brief summary
This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be performed on all subjects. The eligible subject population consists of subjects who have been diagnosed with locally advanced or metastatic melanoma that is refractory to standard therapy or for which no curative standard therapy exists.
Interventions
DRUGTKI258
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of locally advanced or metastatic melanoma (American Joint Committee on Cancer \[AJCC\] stage IIIB, IIIC or IV) that is refractory to standard therapy or for which no curative standard therapy exists. * Measurable disease * Must be eighteen years of age or older * Must meet baseline laboratory requirements * ECOG performance status 0 or 1 * Adults of reproductive potential must agree to use effective contraception or be sterile
Exclusion criteria
* Concurrent therapy with any other investigational agent * Uncontrolled central nervous system metastases * Impaired cardiac function or clinically significant cardiac disease * Received * chemotherapy, targeted therapy or monoclonal antibody therapy ≤4 weeks * biological therapy or immunotherapy (therapeutic or diagnostic) ≤2 weeks * an investigational agent (therapeutic or diagnostic) ≤4 weeks prior to starting study drug or has not recovered from side effects of such therapy * Received any hematopoietic colony-stimulating factor (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin is allowed. * Has undergone major surgery ≤ 2 weeks prior to starting study drug or has not recovered from side effects of such surgery. * Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea, diarrhea, vomiting * Pregnant or breast feeding women * History of another primary malignancy that is currently clinically significant or currently requires active intervention. * Chronic anticoagulation therapy with full strength aspirin, Coumadin, or heparin. * History of thromboembolic or cerebrovascular events within the last 12 months. * History of rectal bleeding, bloody vomit, or spitting up blood within the last 3 months. * Known diagnosis of HIV infection (HIV testing is not mandatory) * Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort and quinidine is prohibited. * Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study-drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, make the patient inappropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose Escalation: Assess tumor response according to RECIST as measured by response rate and lack of early progressive disease (<=2 months) | every 8 weeks |
| Dose Expansion: Determine the plasma and whole blood pharmacokinetics of orally administered TKI258 | PK run-in days 1 & 2, cycle 1 days 1, 8, 15, 16, 28, cycle 2 day 15, cycle 2+ day 28 |
| Dose Expansion: Determine the maximum tolerated dose based on dose limiting toxicity of TKI258 | end of dose escalation |
Secondary
| Measure | Time frame |
|---|---|
| Assess the effect of TKI258 on biomarkers in the blood | PK run day 1 & 2, cycle 1 day 2, 15, 28, cycle 2+ day 28, end of study |
| Assess biomarker changes in tumor/nevi biopsies and archival tumor tissues where accessible, pre- and post-treatment | baseline, cycle 1 day 15, end of study |
| Assess anti-angiogenic effects of TKI258 using DCE-MRI pre- and post-treatment | baseline, cycle 1 day 2 and cycle 2 day 28 |
| Assess changes in tumor glucose metabolism/cell viability between pre- and post-treatment using [18F]-FDG-PET | baseline, cycle 1 day 15, cycle 2 day 28 |
| Assess the safety profile of TKI258 in this patient population | PK run in day 1 & 2, cycle 1 day 8, 15, 28, cycle 2+ day 15 & 28, end of study |
Countries
United States
Outcome results
None listed